Peptoid of Formula I, Pharmaceutical Compositions and Method for Preparation Thereof

1. A novel peptoid targeting multifactorial functions against Alzheimer’s disease
2. Peptoid based therapy advantageous over peptide aspeptoid has higher bioavailability than peptide.
3. Peptoids are stable in human serum protease.
4. Due to their serum stability and lower molecular weight, peptoids may cross the Blood Brain Barrier (BBB).
5. Peptoids are easy to synthesize and the starting materials for their synthesis are very economical.
6. The structural diversity of the peptoidis greater than the peptide.
7. This single peptoid targets the multifactor of the Alzheimer’s disease Therefore, this peptoid can be treated as a potential drug candidate for multifactorial Alzheimer’s disease.

The invention relates to a novel peptoid designed and synthesized to be used as a “multi-target-directed ligand” (MTDL) against this multifactorial complex disease. This peptoid targets most of the factors of AD like inhibition of Ab fibrillations, stabilization of microtubule, inhibition of AChE activity and also reduction of the intracellular reactive oxygen species (ROS). Moreover, peptoids are Oligomers of N-substituted glycine which overcome the metabolic instability, so it has increased bioavailability.

This single peptoid targets  is the multifactor of the Alzheimer’s disease and this peptoid can be treated as a potential drug candidate for multifactorial Alzheimer’s disease.